Related Experiment Video

Updated: Mar 6, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

1.4K

[Azilsartan Medoxomil Capabilities in Arterial Hypertension and Obesity]

Y A Vasyuk1, E Y Shupenina1, V V Nesvetov1

  • 1A.I. Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia.

Kardiologiia
|March 15, 2017
PubMed

Insights

Azilsartan medoxomil effectively lowers blood pressure and improves cardiovascular markers in patients with arterial hypertension and obesity. This study highlights its benefits beyond basic antihypertensive action.

Area of Science:

  • Cardiology
  • Endocrinology
  • Nephrology

Background:

  • Arterial hypertension (AH) is a prevalent cardiovascular disease.
  • Angiotensin II (AT II) mediates negative effects via AT 1 receptors, targeted by Angiotensin Receptor Blockers (ARBs).
  • Variations in AT 1 receptor dissociation influence ARB efficacy, with azilsartan medoxomil showing promise.

Observation:

  • Preclinical studies suggest azilsartan offers benefits beyond blood pressure control, including improved insulin sensitivity and organ protection in obesity.
  • This clinical case examines azilsartan medoxomil's impact on a patient with AH and obesity.

Findings:

  • Azilsartan medoxomil positively influenced clinic and ambulatory blood pressure.
  • Significant improvements were observed in 24-hour aortic stiffness and longitudinal left ventricular strain.
  • The drug demonstrated beneficial effects in a patient with both arterial hypertension and obesity.

Implications:

  • Azilsartan medoxomil may offer multifaceted benefits for patients with arterial hypertension and obesity.
  • Further research into its pleiotropic effects could expand therapeutic applications.
  • This case supports azilsartan medoxomil as a valuable option for managing complex cardiovascular cases.

Keywords:
24-hour central blood pressureaortic stiffnessarterial hypertensionazilsartan medoxomilleft ventricular strain assessmentobesity

More Related Videos

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum Clove and Cuminun cyminum Cumin on C57BL6/j Mice Fed High-Fat Diet13:09

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum Clove and Cuminun cyminum Cumin on C57BL6/j Mice Fed High-Fat Diet

Published on: July 31, 2021

4.1K
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.3K

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.9K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
538
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.7K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
797